UCSF, SeaChange and Novartis have developed a computational approach for large-scale, automated prediction of binding interactions between small molecules and targets that have been associated with adverse drug reactions. The method could help companies improve R&D productivity by pointing to safety signals and helping prioritize candidates in silico.